Career Point International Journal of Research (CPIJR)
©2022 CPIJR | Volume 1 | Issue 5 | ISSN : 2583-1895
Jan-Mar-2026 | DOI: https://doi.org/10.5281/ze 19870960nodo.19871305

Sustained-Release Transdermal Systems for NSAIDS in Musculoskeletal Pain Management

Priyanshu Gupta[1], Manmohan Sharma[2], Anil Ahuja[2], Jyoti Devi[3]

[1]Priyanshu Gupta[1], Manmohan Sharma[2], Anil Ahuja[3],

[1]M. Pharm Scholar, School of Pharmaceutical Studies, Faculty of Health Science, DKNMU, Newai, Rajasthan

[2,]Professor, School of Pharmaceutical Studies, Faculty of Health Science, DKNMU, Newai, Rajasthan

[3]Assistant Professor, School of Pharmaceutical Studies, Faculty of Health Science, DKNMU, Newai, Rajasthan

Corresponding Author: priyanshugupta274417@gmail.com, sharma.manmohan30@gmail.com

Abstract:

Musculoskeletal pain associated with conditions such as arthritis, muscle strain, and sports injuries represents a major cause of disability worldwide and is commonly managed using non-steroidal anti-inflammatory drugs (NSAIDs). However, long-term oral administration of NSAIDs is frequently limited by gastrointestinal irritation, cardiovascular risks, and fluctuating plasma drug levels. Sustained-release transdermal drug delivery systems (TDDS) have emerged as a promising alternative by providing controlled drug release through the skin, bypassing hepatic first-pass metabolism and improving patient compliance. This review summarizes recent advances in sustained-release transdermal NSAID systems for musculoskeletal pain management, with emphasis on formulation design strategies, polymer selection, the role of pressure-sensitive adhesives (PSAs), and in-vitro evaluation methodologies. Key aspects such as matrix and drug-in-adhesive patch designs, polymeric matrices, permeation enhancement approaches, and mechanical performance parameters are discussed. In-vitro and ex-vivo studies demonstrate that optimized transdermal patches can maintain therapeutic drug levels for up to 24 hours, offering continuous analgesic and anti-inflammatory effects while reducing dosing frequency. Clinically, transdermal NSAID delivery provides improved tolerability, reduced gastrointestinal exposure, and enhanced patient adherence, particularly in chronic conditions requiring prolonged therapy. Although challenges related to stability, large-scale manufacturing, and regulatory acceptance persist, ongoing innovations in polymer science and formulation technology are expected to

Career Point International Journal of Research (CPIJR)
©2022 CPIJR | Volume 1 | Issue 5 | ISSN : 2583-1895
Jan-Mar-2026 | DOI: https://doi.org/10.5281/ze 19870960nodo.19871305

accelerate clinical translation. Sustained-release NSAID transdermal systems therefore represent a patient-friendly and effective alternative to conventional oral therapy for long-term musculoskeletal pain management.

Keywords: Sustained-release transdermal patches; NSAIDs; Musculoskeletal pain; Pressure-sensitive adhesives; Polymeric drug delivery systems.

1. Introduction

Musculoskeletal pain represents one of the most common causes of physical disability worldwide and is frequently associated with conditions such as osteoarthritis, rheumatoid arthritis, muscle strain, sports injuries, and lower back pain[1]. These disorders significantly impair mobility and quality of life, particularly among elderly and working populations. Non-steroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of pharmacological management due to their combined analgesic and anti-inflammatory properties. However, conventional oral administration of NSAIDs is often accompanied by gastrointestinal irritation, ulceration, renal impairment, cardiovascular risks, and fluctuating plasma drug levels, especially during long-term therapy. To overcome these limitations, sustained-release transdermal drug delivery systems (TDDS) have gained increasing attention as an alternative route for NSAID administration[2]. Transdermal delivery allows drugs to permeate through the skin directly into systemic circulation, thereby bypassing hepatic first-pass metabolism and minimizing gastrointestinal exposure. This approach enables controlled and prolonged drug release, maintains steady plasma concentrations, reduces dosing frequency, and improves patient adherence through non-invasive application. Moreover, localized delivery to affected tissues may further enhance therapeutic outcomes while limiting systemic toxicity[2,3].

Recent advances in polymer science, pressure-sensitive adhesive (PSA) technology, and formulation strategies have significantly improved the feasibility of sustained-release NSAID transdermal patches. Modern systems are designed to provide consistent drug flux over 24 hours or longer, ensuring continuous pain relief and better compliance in chronic musculoskeletal conditions. The incorporation of suitable polymers, permeation enhancers, and optimized PSA matrices has enabled improved mechanical stability, adhesion, and predictable drug release profiles[3,4]. Sustained-release transdermal NSAID systems are

emerging as promising alternatives to conventional oral therapy for musculoskeletal pain management. Ongoing research focuses on refining patch design, enhancing skin permeation, and establishing robust in-vitro evaluation models to support clinical translation. This growing body of work highlights the potential of transdermal technology to deliver safer, more effective, and patient-friendly pain management solutions[5].

2. Objective of the Review

The objective of this review is to summarize recent advances in sustained-release transdermal systems for NSAIDs used in musculoskeletal pain management, with emphasis on formulation design strategies, polymer selection, the role of pressure-sensitive adhesives (PSAs), in-vitro evaluation methods, and overall therapeutic outcomes.

3. Need of the Study: Conventional oral NSAID therapy often requires repeated dosing and is associated with dose-related adverse effects. Sustained-release transdermal systems address these limitations by:

- Providing prolonged and controlled drug delivery
- Reducing gastrointestinal exposure
- Maintaining uniform plasma drug levels
- Enhancing patient adherence through non-invasive application
- Enabling localized or systemic analgesic and anti-inflammatory action

Given the chronic nature of many musculoskeletal disorders, development of reliable transdermal NSAID platforms is clinically significant for long-term pain management.

4. Design Strategies for Sustained-Release NSAID Patches: Modern NSAID transdermal patches are commonly formulated as matrix systems, drug-in-adhesive systems, or reservoir-type patches, each designed to provide controlled and sustained drug delivery. The primary formulation objective is to achieve predictable release kinetics while maintaining adequate skin compatibility, mechanical strength, and patient comfort[6]. Design strategies emphasize optimization of polymeric matrices, adhesive performance, and drug distribution to ensure consistent therapeutic outcomes. Main formulation consideration includes:

- Selection of polymers with appropriate film-forming and release properties – Polymers must provide sufficient mechanical integrity while allowing controlled diffusion of NSAIDs across the skin.
- Optimization of drug loading to prevent crystallization – Excess drug concentration may lead to crystallization within the matrix, negatively affecting release uniformity and bioavailability[7].

- Incorporation of permeation enhancers to improve skin flux – Enhancers temporarily alter stratum corneum structure, facilitating increased transdermal permeation of NSAIDs.
- Use of plasticizers for flexibility and comfort – Plasticizers such as glycerol or polyethylene glycol reduce brittleness, improve patch elasticity, and enhance patient comfort during prolonged wear[7,8].

In addition, formulation development involves regulating patch thickness, polymer ratios, and drug–polymer interactions to control diffusion pathways. Uniform drug distribution, adequate adhesive strength, and moisture balance are also critical parameters influencing patch performance. Controlled release is achieved primarily by modifying polymer composition, matrix density, and interfacial interactions between the drug and carrier system. Collectively, these strategies enable the development of sustained-release transdermal patches capable of delivering NSAIDs effectively while ensuring stability, comfort, and therapeutic reliability[6-8].

5. Role of Polymers and Pressure-Sensitive Adhesives (PSAs): Polymers constitute the structural foundation of transdermal patches and play a decisive role in determining mechanical strength, flexibility, and drug diffusion characteristics.

- Commonly employed polymers such as hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, Eudragit®, and polyvinylpyrrolidone are favored for their reproducible quality, excellent film-forming ability, and controlled release properties[9].
- These polymers enable precise modulation of NSAID release profiles while ensuring adequate patch integrity and patient comfort. Strategic blending of polymers is often used to optimize elasticity, moisture resistance, and permeation behavior, thereby enhancing overall formulation performance[9,10].
- Pressure-sensitive adhesives (PSAs) perform a dual function by securing the patch to the skin and, in drug-in-adhesive systems, serving as the primary drug-containing matrix. Acrylic, silicone, and rubber-based PSAs are most utilized due to their favorable adhesion properties and chemical stability.
- An ideal PSA should provide consistent adhesion throughout the application period, exhibit compatibility with NSAIDs and other excipients, and allow uniform drug diffusion without compromising skin integrity[10].

PSAs must maintain adhesive performance under varying physiological conditions while minimizing the risk of irritation or sensitization. Proper selection and optimization of

polymers and PSAs are therefore critical to achieving sustained drug release, reliable adhesion, and improved therapeutic efficacy in transdermal NSAID delivery systems.

6. In-Vitro Evaluation of Sustained-Release NSAID Patches: Comprehensive in-vitro evaluation is a critical step in the development of sustained-release transdermal NSAID patches, as it provides essential information regarding formulation quality, release behavior, and predicted clinical performance. These studies help optimize formulation variables and ensure reproducibility before in-vivo investigations[11]. Main In-Vitro Evaluation Parameters are

- **Physical characterization:** Thickness, weight variation, folding endurance, flatness, and surface pH are measured to confirm uniformity, mechanical integrity, and skin compatibility.
- **Mechanical properties:** Tensile strength and percentage elongation are evaluated to assess patch durability and flexibility during prolonged application.
- **Drug content uniformity:** Ensures homogeneous distribution of NSAIDs within the patch matrix[12].
- **Moisture uptake and loss:** Determines formulation stability under varying humidity conditions.
- **In-vitro drug release studies:** Conducted using diffusion cells to characterize sustained-release behavior over extended periods.
- **Ex-vivo skin permeation analysis:** Performed using Franz diffusion cells to estimate drug flux and predict in-vivo transdermal performance[13].
- **Release kinetics modeling:** Drug release data are fitted to zero-order, Higuchi, and Korsmeyer–Peppas models to elucidate the mechanism of release[13,14].

These evaluations provide critical insight into formulation performance, allowing optimization of polymer concentration, patch thickness, and permeation enhancer levels while ensuring batch-to-batch consistency and clinical relevance.

7. Results and Clinical Relevance

Numerous formulation and in-vitro studies have demonstrated that sustained-release transdermal NSAID systems can maintain therapeutically effective plasma drug concentrations for up to 24 hours or longer, thereby significantly reducing dosing frequency while providing continuous analgesic and anti-inflammatory effects.

- Optimized transdermal patches exhibit controlled release profiles, satisfactory mechanical properties, and enhanced skin permeation, supporting their potential for

long-term clinical use. In-vitro and ex-vivo permeation studies consistently report improved drug flux and sustained delivery when appropriate polymers, penetration enhancers, and pressure-sensitive adhesives are employed[15].

- From a clinical perspective, transdermal NSAID delivery offers distinct advantages over conventional oral therapy, including reduced gastrointestinal irritation, avoidance of hepatic first-pass metabolism, and improved tolerability[15,16].
- These benefits translate into enhanced patient compliance, particularly among elderly individuals and patients with chronic musculoskeletal disorders who require prolonged pain management. Additionally, localized drug delivery to affected tissues may further enhance therapeutic outcomes while minimizing systemic exposure[16].

8. Conclusion: Sustained-release transdermal systems represent a promising platform for NSAID delivery in musculoskeletal pain management. Advances in polymer science, PSA technology, and formulation optimization have enabled the development of patches with predictable release profiles and satisfactory skin compatibility. Although challenges related to long-term adhesion, large-scale manufacturing, and regulatory harmonization remain, continued research and quality-by-design approaches are expected to further enhance clinical acceptance. With ongoing innovation, NSAID transdermal patches have strong potential to become reliable, patient-friendly alternatives to conventional oral therapy.

9. References

1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bull World Health Organ*. 2003;81(9):646–56.
2. Vane JR, Botting RM. Mechanism of action of nonsteroidal anti-inflammatory drugs. *Am J Med*. 1998;104(3A):2S–8S.
3. Hawkey CJ. COX-2 inhibitors. *Lancet*. 1999;353(9149):307–14.
4. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol*. 2008;26(11):1261–68.
5. Ita K. Transdermal delivery of drugs with microneedles—potential and challenges. *Pharmaceutics*. 2015;7(3):90–105.
6. Vyas GK, Sharma H, Vyas B, Sharma A, Sharma M. Efficacy of ethanolic extracts for two plants on wound healing in diabetic albino rats. Chettinad Health City Med J. 2023;12(2):46-55.

7. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res. 1996;13(12):1765–69.
8. Chien YW. Transdermal controlled systemic medications. Drugs Pharm Sci. 1987;31:1–35.
9. Satas D. Handbook of Pressure Sensitive Adhesive Technology. 2nd ed. New York: Van Nostrand Reinhold; 1989. p. 1–38.
10. Kaur R, Garg T, Rath G, Goyal AK. Development and evaluation of transdermal patch for herbal drugs. Asian Pac J Trop Biomed. 2012;2(3 Suppl):S1711–19.
11. Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. *Int J Pharm*. 2005;305(1–2):2–12.
12. Bharti K, Sharma M, Vyas GK, Sharma S. Phytochemical screening of alcoholic extract of Thuja occidentalis leaves for formulation and evaluation of wound healing ointment. Asian Journal of Pharmaceutical Research and Development. 2022 Apr 15;10(2):17-22.
13. Thacharodi D, Rao KP. Development and in vitro evaluation of chitosan-based transdermal drug delivery systems for controlled delivery of propranolol hydrochloride. *Biomaterials*. 1995;16(2):145–48.
14. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. *Eur J Pharm Sci*. 2001;13(2):123–33.
15. Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. *Ther Deliv*. 2010;1(1):109–31.
16. Rhee YS, Choi JG, Park ES, Chi SC. Transdermal delivery of diclofenac sodium using eutectic mixture of lidocaine and prilocaine. *J Control Release*. 2001;71(3):231–41.